May, June, and July have produced U.S. court decisions with significant consequences for Japanese companies doing business in or trading with the United States, from the unwinding of the IEEPA tariff regime to a nine-figure antitrust verdict against a major Japanese pharmaceutical company. We summarize five developments that could prompt a call from your clients.
Authors:
Donald W. Hawthorne (hawthorne@clm.com)